Cyclosporine or tacrolimus: Which is the better partner for Myfortic or CellCept?

P. C. Lee; S. S. Chang; S. C. Shieh; Z. C. Wu; W. M. Wang; J. D. Wang; C. J. Hung; Y. J. Lin; T. C. Chou; R. H. Chan

doi:10.1016/j.transproceed.2011.12.023

Cyclosporine or tacrolimus: Which is the better partner for Myfortic or CellCept?

P. C. Lee, S. S. Chang, S. C. Shieh, Z. C. Wu, W. M. Wang, J. D. Wang, C. J. Hung, Y. J. Lin, T. C. Chou, R. H. Chan

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Background: Mycophenolic acid (MPA) pharmacokinetics using the mycophenolate mofetil (CellCept) formulation are known to differ between patients receiving tacrolimus (FK) or cyclosporine (CyA), but only limited data exist concerning concomitant use of FK or CyA with enteric-coated mycophenolate sodium (EC-MPS; Myfortic). This retrospective study compared the drug interactions with the mycophenolic acid blood levels using different immunosuppressants and their relation to graft survival. Patients and methods: We studied MPA levels in posttransplant sera from 298 renal transplant recipients. Results: Patients receiving immunosuppression with CyA + Myfortic showed 94% at 5- and 10-year graft survivals, which were better than CyA + CellCept (75%, 63%). This combination suppressed posttransplant human leukocyte antigen (HLA) antibody development significantly (P =.03) with higher MPA levels. Conclusion: Patients immunosuppressed with CyA + Myfortic showed higher MPA levels and lower posttransplant HLA antibody development as well as the best graft survival. CyA + Myfortic or FK + Cellcept may be better combinations.

Original language	English
Pages (from-to)	137-139
Number of pages	3
Journal	Transplantation Proceedings
Volume	44
Issue number	1
DOIs	https://doi.org/10.1016/j.transproceed.2011.12.023
Publication status	Published - Jan 2012
Externally published	Yes

ASJC Scopus subject areas

Surgery
Transplantation

Access to Document

10.1016/j.transproceed.2011.12.023

Cite this

@article{1ee38ccb090a4e3cae7390926c5869a5,

title = "Cyclosporine or tacrolimus: Which is the better partner for Myfortic or CellCept?",

abstract = "Background: Mycophenolic acid (MPA) pharmacokinetics using the mycophenolate mofetil (CellCept) formulation are known to differ between patients receiving tacrolimus (FK) or cyclosporine (CyA), but only limited data exist concerning concomitant use of FK or CyA with enteric-coated mycophenolate sodium (EC-MPS; Myfortic). This retrospective study compared the drug interactions with the mycophenolic acid blood levels using different immunosuppressants and their relation to graft survival. Patients and methods: We studied MPA levels in posttransplant sera from 298 renal transplant recipients. Results: Patients receiving immunosuppression with CyA + Myfortic showed 94% at 5- and 10-year graft survivals, which were better than CyA + CellCept (75%, 63%). This combination suppressed posttransplant human leukocyte antigen (HLA) antibody development significantly (P =.03) with higher MPA levels. Conclusion: Patients immunosuppressed with CyA + Myfortic showed higher MPA levels and lower posttransplant HLA antibody development as well as the best graft survival. CyA + Myfortic or FK + Cellcept may be better combinations.",

author = "Lee, {P. C.} and Chang, {S. S.} and Shieh, {S. C.} and Wu, {Z. C.} and Wang, {W. M.} and Wang, {J. D.} and Hung, {C. J.} and Lin, {Y. J.} and Chou, {T. C.} and Chan, {R. H.}",

year = "2012",

month = jan,

doi = "10.1016/j.transproceed.2011.12.023",

language = "English",

volume = "44",

pages = "137--139",

journal = "Transplantation Proceedings",

issn = "0041-1345",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Cyclosporine or tacrolimus

T2 - Which is the better partner for Myfortic or CellCept?

AU - Lee, P. C.

AU - Chang, S. S.

AU - Shieh, S. C.

AU - Wu, Z. C.

AU - Wang, W. M.

AU - Wang, J. D.

AU - Hung, C. J.

AU - Lin, Y. J.

AU - Chou, T. C.

AU - Chan, R. H.

PY - 2012/1

Y1 - 2012/1

N2 - Background: Mycophenolic acid (MPA) pharmacokinetics using the mycophenolate mofetil (CellCept) formulation are known to differ between patients receiving tacrolimus (FK) or cyclosporine (CyA), but only limited data exist concerning concomitant use of FK or CyA with enteric-coated mycophenolate sodium (EC-MPS; Myfortic). This retrospective study compared the drug interactions with the mycophenolic acid blood levels using different immunosuppressants and their relation to graft survival. Patients and methods: We studied MPA levels in posttransplant sera from 298 renal transplant recipients. Results: Patients receiving immunosuppression with CyA + Myfortic showed 94% at 5- and 10-year graft survivals, which were better than CyA + CellCept (75%, 63%). This combination suppressed posttransplant human leukocyte antigen (HLA) antibody development significantly (P =.03) with higher MPA levels. Conclusion: Patients immunosuppressed with CyA + Myfortic showed higher MPA levels and lower posttransplant HLA antibody development as well as the best graft survival. CyA + Myfortic or FK + Cellcept may be better combinations.

AB - Background: Mycophenolic acid (MPA) pharmacokinetics using the mycophenolate mofetil (CellCept) formulation are known to differ between patients receiving tacrolimus (FK) or cyclosporine (CyA), but only limited data exist concerning concomitant use of FK or CyA with enteric-coated mycophenolate sodium (EC-MPS; Myfortic). This retrospective study compared the drug interactions with the mycophenolic acid blood levels using different immunosuppressants and their relation to graft survival. Patients and methods: We studied MPA levels in posttransplant sera from 298 renal transplant recipients. Results: Patients receiving immunosuppression with CyA + Myfortic showed 94% at 5- and 10-year graft survivals, which were better than CyA + CellCept (75%, 63%). This combination suppressed posttransplant human leukocyte antigen (HLA) antibody development significantly (P =.03) with higher MPA levels. Conclusion: Patients immunosuppressed with CyA + Myfortic showed higher MPA levels and lower posttransplant HLA antibody development as well as the best graft survival. CyA + Myfortic or FK + Cellcept may be better combinations.

UR - http://www.scopus.com/inward/record.url?scp=84863345151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863345151&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2011.12.023

DO - 10.1016/j.transproceed.2011.12.023

M3 - Article

C2 - 22310598

AN - SCOPUS:84863345151

SN - 0041-1345

VL - 44

SP - 137

EP - 139

JO - Transplantation Proceedings

JF - Transplantation Proceedings

IS - 1

ER -

Cyclosporine or tacrolimus: Which is the better partner for Myfortic or CellCept?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this